Aspirin for the prevention of cardiovascular morbidity

Minerva Medica

Volumn 101, Issue 4, 2010, Pages 205-214

  Sanchez Ross, M ^a   Waller, A H ^a   Maher, J ^a   Klapholz, M ^a   Haider, B ^a   Kaluski, E ^a  

^a University of Medicine and Dentistry of New Jersey   (United States)

Author keywords

Aspirin; Cardiovascular diseases; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT;

ACUTE CORONARY SYNDROME; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERTENSION; LOW DRUG DOSE; MORBIDITY; MORTALITY; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK REDUCTION; SEX DIFFERENCE; THROMBOSIS;

ASPIRIN; CARDIOVASCULAR DISEASES; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; THROMBOSIS;

EID: 79251519990     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002;106:388-91.
2. NICE: The National Collaborating Centre for Chronic Conditions, 2008. Type 2 diabetes. National clinical guideline for management in primary and secondary care (update) [cited 2010 July 26]. Available from: http://www.nice.org.uk/nicemedia/pdf/CG-66NICEGuideline.pdf
3. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD et al.; American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008;52:1502-17.
4. Becker RC, Meade TW, Berger PB, Ezekowitz M, O'Connor CM, Vorchheimer DA et al.; American College of Chest Physicians. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl):776S-814S.
5. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomized trials. Heart 2001;85:265-71.
6. British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(Suppl 5):v1-52.
7. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R et al.; European Society of Cardiology (ESC); European Association for Cardiovascular Prevention and Rehabilitation (EACPR); Council on Cardiovascular Nursing; European Association for Study of Diabetes (EASD); International Diabetes Federation Europe (IDF-Europe); European Stroke Initiative (EUSI); Society of Behavioral Medicine (ISBM); European Society of Hypertension (ESH); WONCA Europe (European Society of General Practice/Family Medicine); European Heart Network (EHN); European Atherosclerosis Society (EAS). European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007;14(Suppl 2):S1-113.
8. NICE: The National Collaborating Centre for Chronic Conditions, 2008. Type 2 diabetes. National clinical guideline for management in primary and secondary care (update) [cited 2010 July 26]. Available at: http://www.nice.org. uk/nicemedia/pdf/CG66NICEGuideline.pdf
9. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-60.
10. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106. (Pubitemid 24052591)
11. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
12. Hart RG, Halperin JL, McBride R, Benavente O, Man-Son-Hing M, Kronmal RA. Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypothesis. Arch Neurol 2000;57:326-32. (Pubitemid 30140518)
13. Eidelman RS, Hebert PR, Weisman SM, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 2003;163:2006-10.
14. Peto R, Gray R, Collins R. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988;296:313-6.
15. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321:129-35.
16. [No authors listed] Aspirin for primary prevention of cardiovascular disease? Evid Based Med 2010;15:31-3.
17. De Abajo FJ, Garcia Rodriguez LA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clinical Pharmacology 2001 [Epub ahead of print].
18. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:161-72.
19. Wolff T, Miller T, Ko S. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. US Preventive Services Task Force. Ann Intern Med 2009;150:396-404.
20. Medicines and Healthcare products Regulatory Agency, 2009. Aspirin: not licensed for primary prevention of thrombotic vascular disease. Drug Safety Update 2009;3:10-1.
21. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk. Lancet 1998;351:233-41.
22. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62.
23. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001;357:89-95.
24. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-304.
25. Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC et al.; Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010;303:841-8.
26. Dalen JE. Aspirin for the primary prevention of stroke and myocardial infarction: ineffective or wrong dose? Am J Med 2010;123:101-2.
27. REACH registry. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180-9.
28. REACH registry. Steg PG, Bhatt DL, Wilson PW, D'Agostino R Sr, Ohman EM, Rother J et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007;297:1197-206.
29. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006;295:306-13- (Pubitemid 43112959)
30. ETDRS Investigators. Aspirin effects on mortality and morbidity on patients with diabetes mellitus. Early Treatment Diabetes Retinopathy Study Report 14. JAMA 1992;268:1292-300.
31. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R et al.; Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008;337:a1840. doi: 10.1136/bmj.a1840.
32. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N et al.; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes OPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008;300:2134-41.
33. Calvin AD, Aggarwal NR, Murad MH, Shi Q, Elamin MB, Geske JB et al. Aspirin for primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care 2009;32:2300-6.
34. De Berardis G, Sacco M, Strippoli GF, Pellegrini F, Graziano G, Tognoni G et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomized controlled trials. BMJ 2009;339:b4531. doi: 10.1136/bmj.b4531.
35. Song SH, Gray TA, Tesfaye S. Time to rethink aspirin in diabetes? BMJ 2009;339:b5588.
36. Felmeden DC, Lip GY. Antithrombotic therapy in hypertension: a Cochrane Systematic review. J Hum Hypertens 2005;19:185-96.
37. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336:827-30.
38. Juul-Möller S, Edvardsson N, Jahnmatz B, Rosén A, Sørensen S, Omblus R. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992;340:1421-5.
39. Lewis HD Jr, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE 3rd et al. Protective effects of aspirin against myocardial infarction and death in men with unstable angina. Results of a Veterans Administration cooperative study. N Engl J Med 1983;309:396-403.
40. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke. Lancet 1997;349:1641-9.
41. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European stroke prevention study. 2. dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.